Uterine Cervix Cancer

  • Brittaney-Belle E. Gordon
  • Orit Kaidar-Person
  • Mahesh Varia
  • Ashley A. WeinerEmail author


While early-stage cervical cancer can be managed surgically, locally advanced cervical cancer is treated with definitive EBRT with concurrent chemotherapy and brachytherapy. High-dose rate brachytherapy is a technique that enables delivery of high-dose, hypofractionated radiotherapy directly to the cervical tumor. Advances in brachytherapy include 3D imaging, which enables delineation of adjacent organs at risk (CT or MRI) and the cervical tumor (MRI). In this chapter, we review the usage of high-dose rate (HDR) intracavitary brachytherapy in the treatment of cervical carcinoma.


Uterine cervix Intracavitary brachytherapy Interstitial brachytherapy Cervical carcinoma High-dose rate (HDR) EBRT 


  1. 1.
    Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in Cervical Cancer in the United States. Int J Radiat Oncol. 2013;87(1):111–9. Scholar
  2. 2.
    Tanderup K, Fokdal LU, Sturdza A, et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol. 2016;120:441–6. Scholar
  3. 3.
    Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervical cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 1992;25:273–9.CrossRefGoogle Scholar
  4. 4.
    Viswanathan AN, Beriwal S, De Los Santos JF, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012;11:47–52. Scholar
  5. 5.
    Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74:235–45. Scholar
  6. 6.
    Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations Committee; American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix Part I: general principles. Brachytherapy. 2012;11:33–46. Scholar
  7. 7.
    Potter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67–77. Scholar
  8. 8.
    Small W, Beriwal S, Demanes DJ, et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy. 2012;11(1):58–67. Scholar
  9. 9.
    Higginson DS, Morris DE, Jones EL, Clarke-Pearson D, Varia MA. Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology. Gynecol Oncol. 2011;120:404–12. Scholar
  10. 10.
    Halle JS, Rosenman JG, Varia MA, Fowler WC, Walton LA, Currie JL. 1000 cGy single dose palliation for advanced carcinoma of the cervix or endometrium. Int J Radiat Oncol Biol Phys. 1986;12(11):1947–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Boulware RJ, Caderao JB, Delclos L, Wharton JT, Peters LJ. Whole pelvis megavoltage irradiation with single doses of 1000 rad to palliate advanced gynecologic cancers. Int J Radiat Oncol Biol Phys. 1979;5(3):333–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Chafe W, Fowler WC, Currie JL, Davis ML, Walton LA, Montana G. Single-fraction palliative pelvic radiation therapy in gynecologic oncology: 1,000 rads. Am J Obstet Gynecol. 1984;148(5):701–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Mazeron R, Fokdal LU, Kirchheiner K, et al. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: results from the prospective multicenter EMBRACE study. Radiother Oncol. 2016;120:412–9. Scholar
  14. 14.
    Kirchheiner K, Nout RA, Lindegaard JC, et al. Dose–effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol. 2016;118(1):160–6. Scholar
  15. 15.
    Liberrman D, Mehus B, Eliott S. Urinary adverse effects of pelvic radiotherapy. Transl Androl Urol. 2014;3(2):186–95.Google Scholar
  16. 16.
    Liu R, Wang X, Tian JH, et al. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev. 2014;10:CD007563. Scholar
  17. 17.
    Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872–80. Scholar
  18. 18.
    Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53. Scholar
  19. 19.
    Jorcano S, Molla M, Escude L, et al. Hypofractionated extracranial stereotactic radiotherapy boost for gynecologic tumors: a promising alternative to high-dose rate brachytherapy. Technol Cancer Res Treat. 2010;9:509–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Kunos CA, Brindle J, Waggoner S, et al. Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies. Front Oncol. 2012;2:181. Scholar
  21. 21.
    Dewas S, Bibault J, Mirabel X, et al. Robotic image-guided reirradiation of lateral pelvic recurrences: preliminary results. Radiat Oncol. 2011;6(1):77. Scholar
  22. 22.
    Choi CW, Cho CK, Yoo SY, et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys. 2009;74:147–53. Scholar
  23. 23.
    Mesko S, Sandler K, Cohen J, Konecny G, Steinberg M, Kamrava M. Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies. Int J Gynecol Cancer. 2017;27(2):403–8. Scholar
  24. 24.
    Badakh DK, Grover AH. Reirradiation with high-dose-rate remote afterloading brachytherapy implant in patients with locally recurrent or residual cervical carcinoma. J Cancer Res Ther. 2009;5:24–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Zolciak-Siwinska A, Bijok M, Jonska-Gmyrek J, et al. HDR brachytherapy for the reirradiation of cervical and vaginal cancer: analysis of efficacy and dosage delivered to organs at risk. Gynecol Oncol. 2014;132:93–7. Scholar
  26. 26.
    Mabuchi S, Takahashi R, Isohashi F, et al. Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer: a single institutional experience. Int J Gynecol Cancer. 2014;24:141–8. Scholar
  27. 27.
    Kim DH, Lee JH, Ki YK, et al. Short-course palliative radiotherapy for uterine cervical cancer. Radiat Oncol J. 2013;31:216–21. Scholar
  28. 28.
    Grigsby PW, Portelance L, Williamson JF. High dose ratio (HDR) cervical ring applicator to control bleeding from cervical carcinoma. Int J Gynecol Cancer. 2002;12(1):18–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Brittaney-Belle E. Gordon
    • 1
  • Orit Kaidar-Person
    • 2
    • 3
  • Mahesh Varia
    • 2
  • Ashley A. Weiner
    • 2
    Email author
  1. 1.University of North Carolina School of MedicineChapel HillUSA
  2. 2.Department of Radiation OncologyUniversity of North Carolina School of MedicineChapel HillUSA
  3. 3.Oncology Institute Radiation Oncology and Neuro-Oncology UnitRambam Medical CenterHaifaIsrael

Personalised recommendations